Description
This active molecular is a leukotriene antagonist with the IC50 of 3 nM in human polymorphonuclear leukocytes. MK-886 also inhibits PPARα activation. Inhibition of 5-lipoxygenase-activating protein (FLAP) leads to inhibited 5-lipoxygenase (5-LOX), and this may help in treating atherosclerosis. MK-886 and Celecoxib have an inhibitory effect on the growth of pancreatic cancer cell line SW1990 and angiogenesis. In Mar 1996, an animal study had been added to the Ischaemic Heart Disease pharmacodynamics section